XML 30 R19.htm IDEA: XBRL DOCUMENT
v3.23.2

Subsequent Event | 6 Months Ended
--- | ---
Jun. 30, 2023
Subsequent Events [Abstract] |
Subsequent Event | 12. Subsequent Event In July 2023, the Company expanded its current licensing agreement for trofinetide with Neuren to acquire rights to the drug outside of North America as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. Under the terms of the expanded agreement, Neuren will receive an upfront payment of $100.0 million and is eligible to receive up to the following additional milestone payments based on the achievement of certain development and sales milestones (in thousands):
|  | Trofinetide |  |  | NNZ-2591 |
Development milestones |  | $ | — |  |  | $ | 15,000 |
First commercial sale milestones |  |  |  |  |  |
North America |  |  | — |  |  |  | 40,000 |
Europe |  |  | 45,000 |  |  |  | 45,000 |
Japan |  |  | 18,750 |  |  |  | 18,750 |
Sales milestones |  |  |  |  |  |
North America |  |  | — |  |  |  | 350,000 |
Europe |  |  | 170,000 |  |  |  | 170,000 |
Japan |  |  | 110,000 |  |  |  | 110,000 |
Rest of World |  |  | 82,500 |  |  |  | 82,500 |
Total milestone payments |  | $ | 426,250 |  |  | $ | 831,250 |
In addition, the Company will be required to pay Neuren tiered royalties from the mid-teens to low-twenties percent of trofinetide net sales outside of North America. Percentage royalties related to NNZ-2591 net sales are identical to the trofinetide in each of North America and outside North America.

X
- References No definition available. + Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration